First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: A systematic review

Journal of Thoracic Oncology

Volumn 5, Issue 2, 2010, Pages 260-274

  Goffin, John ^a   Lacchetti, Christina ^a   Ellis, Peter M ^a   Ung, Yee C ^b   Evans, William K ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

Non small cell lung cancer (NSCLC); Systematic review; Systemic chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; APRINOCARSEN; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; MITOMYCIN; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; PROTEIN KINASE C ALPHA; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VINDESINE;

ADVANCED CANCER; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONSTIPATION; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG TOXICITY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; HAIR LOSS; HAZARD RATIO; HEMOPTYSIS; HUMAN; HYPOKALEMIA; INFORMATION RETRIEVAL; KIDNEY DISEASE; LEUKOPENIA; LONG TERM CARE; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MEDLINE; META ANALYSIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PERIPHERAL NEUROPATHY; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOCYTE; THROMBOCYTOPENIA; TOXICITY; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

EID: 77649104920     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181c6f035     Document Type: Review

References (83)

1. Carney DN, Hansen HH. Non-small-cell lung cancer-stalemate or progress? N Engl J Med 2000;343:1261-1262.
2. Delbaldo C, Michiels S, Syz N, et al. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-smallcell lung cancer: a meta-analysis. JAMA 2004;292:470-484.
3. Fallowfield LJ, Harper P. Health-related quality of life in patients undergoing drug therapy for advanced non-small-cell lung cancer. Lung Cancer 2005;48:365-377.
4. Dranitsaris G, Cottrell W, Evans WK. Cost-effectiveness of chemotherapy for nonsmall-cell lung cancer. Curr Opin Oncol 2002;14:375-383.
5. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004;350:379-392.
6. The AGREE Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care 2003;12:18-23.
7. Oxman AD, Guyatt GH, Singer J, et al. Agreement among reviewers of review articles. J Clin Epidemiol 1991;44:91-98.
8. Scottish Intercollegiate Guidelines Network. Management of Patients With Lung Cancer: A National Clinical Guideline. Scotland, United Kingdom: Scottish Intercollegiate Guidelines Network; 2005.
9. Socinski MA, Crowell R, Hensing TE, et al. Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132:277S-289S.
10. Ardizzoni A, Boni L, Tiseo M, et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007;99:847-857.
11. Baggstrom MQ, Stinchcombe TE, Fried DB, et al. Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis. J Thorac Oncol 2007;2:845-853.
12. Douillard JY, Laporte S, Fossella F, et al. Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials. J Thorac Oncol 2007;2:939-946.
13. Jiang J, Liang X, Zhou X, et al. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer 2007;57: 348-358.
14. Soon YY, Askie L, Stockler M, et al. Optimal duration of chemotherapy for advanced non-small cell lung cancer: A systematic review and meta-analysis (abstract). J Thorac Oncol 2007;2 (8 suppl 4):S450-S451.
15. Pujol JL, Barlesi F, Daures JP. Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials. Lung Cancer 2006;51:335-345.
16. D'Addario G, Pintilie M, Leighl NB, et al. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 2005;23: 2926-2936.
17. Le Chevalier T, Scagliotti G, Natale R, et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 2005;47:69-80.
18. Hotta K, Matsuo K, Ueoka H, et al. Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004;22:3852-3859.
19. Hotta K, Matsuo K, Ueoka H, et al. Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: a literature based meta-analysis of randomised trials. Ann Oncol 2004;15: 1782-1789.
20. Alberola V, Camps C, Provencio M, et al. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol 2003;21:3207-3213.
21. Belani CP, Larocca RV, Rinaldi DA, et al. A multicenter, phase III randomized trial for stage IIIB/IV NSCLC of weekly paclitaxel and carboplatin vs. standard paclitaxel and carboplatin given every three weeks, followed by weekly paclitaxel [abstract]. Proc Am Soc Clin Oncol 2004;22:621s.
22. Belani CP, Lee JS, Socinski MA, et al. Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer. Ann Oncol 2005;16:1069-1075.
23. Booton R, Lorigan P, Anderson H, et al. A phase III trial of docetaxel/ carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-smallcell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1). Ann Oncol 2006;17:1111-1119.
24. Brodowicz T, Krzakowski M, Zwitter M, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial. Lung Cancer 2006;52:155-163.
25. Comella P, Frasci G, Carnicelli P, et al. Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients. Br J Cancer 2004; 91:489-497.
26. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 1999;91:66-72.
27. Fidias P, Dakhil S, Lyss A, et al. Phase III study of immediate versus delayed docetaxel after induction therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer: Updated report with survival [abstract]. Proc Am Soc Clin Oncol 2007;25:388s.
28. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003;21:3016-3024.
29. Frasci G, Lorusso V, Panza N, et al. Gemcitabine plus vinorelbine yields better survival outcome than vinorelbine alone in elderly patients with advanced non-small cell lung cancer: a Southern Italy Cooperative Oncology Group (SICOG) phase III trial. Lung Cancer 2001;34:S65-S69.
30. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007;25:1545-1552.
31. Gebbia V, Galetta D, Caruso M, et al. Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale. Lung Cancer 2003;39:179-189.
32. Giaccone G, Herbst R, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004;22:777-784.
33. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003;95:362-372.
34. Hainsworth JD, Spigel DR, Farley C, et al. Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer: a randomized phase 3 trial of the Minnie Pearl Cancer Research Network. Cancer 2007;110:2027-2034.
35. Helbekkmo N, Sundstrom SH, Aasebo U, et al. Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer 2007;97:283-289.
36. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004;22:785-794.
37. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-5899.
38. Ichinose Y, Nishiwaki Y, Kunitoh H, et al. A multicenter randomized phase III trial of docetaxel cisplatin (DP) vs. vindesine cisplatin (VP) in patients with untreated stage IV non-small cell lung cancer (NSCLC) (abstract). Ann Oncol 2002;13 (suppl 5):132-133.
39. Kawahara M, Ogawara M, Nishiwaki Y, et al. Phase III randomized study of vinorelbine (V), gemcitabine (G) followed by docetaxel (D) (VGD) versus paclitaxel (P) and carboplatin (C) (PC) in patients (pts) with advanced non-small cell lung cancer (NSCLC) (Japan Multinational Trial Organization LC00-03) [abstract]. Proc Am Soc Clin Oncol 2006;24:367s.
40. Kim JH, Kim SY, Jung KH, et al. Randomized phase 3 study of gemcitabine plus cisplatin versus etoposide plus cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer: Korean Cancer Study Group experience (abstract). Lung Cancer 2006; 52:75-81.
41. Kudoh S, Takeda K, Nakagawa K, et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-smallcell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 2006;24:3657-3663.
42. Laack E, Dickgreber N, Muller T, et al. Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group. J Clin Oncol 2004;22: 2348-2356.
43. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Onc 2009;27: 1227-1234.
44. Martoni A, Marino A, Sperandi F, et al. Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer. Eur J Cancer 2005;41:81-92.
45. Melo M, Barradas P, Costa A, et al. Results of a randomized phase III trial comparing 4 cisplatin (P)-based regimens in the treatment of locally advanced and metastatic non-small cell lung cancer (NSCLC): mitomycin/ vinblastine/cisplatin (MVP) is no longer a therapeutic option (abstract). Proc Am Soc Clin Oncol 2002;21:302a.
46. Novello S, Bruzzi P, Barone C, et al. Phase III study in stage IV non-small-cell lung cancer patients treated with two courses of cisplatin/ gemcitabine followed by a randomization to three additional courses of the same combination or gemcitabine alone. Ann Oncol 2007;18:903-908.
47. Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 2007; 18:317-323.
48. Park HS, Lee SJ, Kim JH, et al. Randomized trial of docetaxel plus cisplatin (DC) versus etoposide plus cisplatin (EC) in locally advanced, recurrent, or metastatic non-small cell lung cancer (NCSLC) (abstract). Eur J Cancer 2003;1:S240.
49. Park JO, Kim SW, Ahn JS, et al. Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. J Clin Oncol 2007;25:5233-5239.
50. Paz-Ares L, Douillard JY, Koralewski P, et al. Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase c-alpha antisense oligonucleotide, in patients with advanced-stage nonsmall- cell lung cancer. J Clin Oncol 2006;24:1428-1434.
51. Rigas J, Dragnev K, Kerry M. Survival equivalence of non-platinumbased and platinum-based chemotherapy for advanced non-small-cell lung cancer (NSCLC): the results of a multicenter internet-based phase III randomized study (D0112) (abstract). Lung Cancer 2005;49:S35.
52. Rubio JE, Sahagun G. A randomized phase III trial comparing docetaxel carboplatin (DCP) vs vinorelbine carboplatin (VCP) in non small cell lung cancer (NSCLC) stage III and IV (abstract). Proc Am Soc Clin Oncol 2003;22:703.
53. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355: 2542-2550.
54. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002;20:4285-4291.
55. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98.
56. Schuette W, Blankenburg T, Guschall W, et al. Multicenter randomized trial for stage IIIB/IV non-small-cell lung cancer using every-3-week versus weekly paclitaxel/carboplatin. Clin Lung Cancer 2006;7:338-343.
57. Sculier JP, Lafitte JJ, Lecomte J, et al. A three-arm phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small-cell lung cancer. Ann Oncol 2002; 13:874-882.
58. Souquet PJ, Tan EH, Rodrigues Pereira J, et al. GLOB-1: a prospective randomised clinical phase III trial comparing vinorelbine-cisplatin with vinorelbine-ifosfamide-cisplatin in metastatic non-small-cell lung cancer patients. Ann Oncol 2002;13:1853-1861.
59. Tan EH, Szczesna A, Krzakowski M, et al. Randomized study of vinorelbine- gemcitabine versus vinorelbine-carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 2005;49:233-240.
60. Treat J. A randomized phase III trial of gemcitabine (G) in combination with carboplatin (C) or paclitaxel (P) versus paclitaxel plus carboplatin in advanced (stage IIIB, IV) non-small cell lung cancer (NSCLC) (abstract). Proc Am Soc Clin Oncol 2003;21:624.
61. Tsukada H, Yokoyama A, Nishiwaki Y, et al. Randomized controlled trial comparing docetaxel (D)-cisplatin (P) combination with D alone in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC): JCOG0207 [abstract]. Proc Am Soc Clin Oncol 2007;25: 416s.
62. von Plessen C, Bergman B, Andresen O, et al. Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. Br J Cancer 2006;95: 966-973.
63. Westeel V, Quoix E, Moro-Sibilot D, et al. Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer. J Natl Cancer Inst 2005;97:499-506.
64. Takiguchi Y. The final results of a randomized phase III trial comparing irinotecan (CPT-11) and cisplatin (CDDP) with vindesine (VDS) and CDDP in advanced non-small cell lung cancer (NSCLC). Lung Cancer 2000;29:28.
65. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small cell lung cancer (FLEX): an openlabel randomised phase III trial. Lancet 2009;373:1525-1531.
66. Hirsh FR, Herbst RS, Olsen C, et al. Increased EGFR gene copy number detected by fluorescent in site hybridization predicts outcome in nonsmall- cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol 2008;26:3351-3357.
67. Belani CP, Brodowicz T, Ciuleanu T, et al. Maintenance pemetrexed (Pem) plus best supportive case (BSC) versus placebo (Plac) plus BSC: a randomized phase III study in andanved non-small cell lung cancer (NSCLC). J Clin Oncol 2009;27:18s, (abstract CRA 8000).
68. O'Byrne KJ, Bondarenko I, Barrios C, et al. Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): Data from the Flex study (abstract). Proc Am Soc Clin Oncol 2009;27:15s.
69. Patel T, Dreisbach L, McCleod M, et al. Lung cancer symptoms with cetuximab/taxane/carboplatin in first-line advanced NSCLC: Analysis of the BMS099 trial. Proc Am Soc Clin Oncol 2009;27 (suppl):abstract e19011.
70. Lilenbaum RC, Herndon JE II, List MA, et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: The Cancer and Leukemia Group B (study 9730). J Clin Oncol 2005;23: 190-196.
71. Kubota K, Watanabe K, Kunitoh H, et al. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 2004;22:254-261.
72. Bareschino MA, Schettino C, Troiani T, Martinelli E, Morgillo F, Ciardiello F. Erlotinib in cancer treatment. Ann Oncol 2007;18:vi35- vi41.
73. ten Bokkel Huinink WW, Bergman B, Chemaissani A, et al. Singleagent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic nonsmall cell lung cancer. Lung Cancer 1999;26:85-94.
74. Negoro S, Masuda N, Takada Y, et al. Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br J Cancer 2003;88:335-341.
75. Smith IE, O'Brien ME, Talbot DC, et al. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 2001;19:1336-1343.
76. Socinski MA, Schell MJ, Peterman A, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 2002;20:1335-1343.
77. Vansteenkiste J, Vandebroek J, Nackaerts K, et al. Influence of cisplatinuse, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: detailed symptom analysis of a randomised study comparing cisplatin-vindesine to gemcitabine. Lung Cancer 2003;40:191-199.
78. Comella P, Filippelli G, De Cataldis G, et al. Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-smallcell lung cancer: a phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101). Ann Oncol 2007;18:324-330.
79. Georgoulias V, Ardavanis A, Tsiafaki X, et al. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 2005;23:2937-2945.
80. Kosmidis P, Mylonakis N, Nicolaides C, et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 2002;20:3578-3585.
81. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy- naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
82. Peterson P, Park K, Fossella F, et al. Is pemetrexed more effective in patients with non-squamous histology? A retrospective analysis of a phase III trial of pemetrexed vs. docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC) (abstract). Proc Am Soc Clin Oncol 2007;25:363.
83. Ciuleanu TE, Brodowicz T, Belani CP, et al. Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: a phase III study (abstract). Proc Am Soc Clin Oncol 2008;26:8011.